InvestWiser

Xintela AB

XINTNasdaq StockholmHealthcareMarket value 123 m SEK
0.14SEK +1.8%
last day · Price as of 18 November 2026

The answer first

Does Xintela beat the market?

No, Xintela has not beaten the market over the last year.

Xintela−45.2%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 3% of Nordic stocks

    • Quality44
    • Value0
    • Trend9

    No. 182 of 195 in healthcare

Max for seven days

Follow Xintela with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Xintela

From today, at a price of 0.14 SEK. Write why you follow Xintela, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Xintela

Your first answer is free, no account needed.

Do you own Xintela, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Xintela and a few more. Free, no card.

Past year against the exchange and Super Stock
Xintela−45.2%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Xintela has fallen 45.2% over the past year, including dividends.
  • Overall, Xintela ranks better than 3% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 88.8%. The price is 97.0% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

3

Quality, value and trend together. Better than 3% of Nordic stocks.

No. 182 of 195 in healthcare

Quality44
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 140 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity−1.10
  • Asset turnoverSales divided by everything the company owns0.09
  • Return on equityProfit divided by equity−175.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value0
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 196 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equitynegative earnings
  • P/SPrice divided by sales38.7
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend9
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 158 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−23.4%
  • 6 months−45.2%
  • 9 months−47.8%
  • 12 months−45.2%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−13.1%
3 years, per year
−16.4%
5 years, per year
−36.4%
10 years, per year
−22.7%
Largest fall, 3 years
−88.8%
From a peak to the bottom
From the peak now
−97.0%
How far the price is from the peak
Volatility, 1 year
64.5%
How much the price swings over a year
Beta, 1 year
0.69
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Xintela

One fund we follow owns Xintela. The share is how much of the fund the stock makes up.

  • Sweden1

From the funds' latest known holdings.

About Xintela

Xintela AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 11 employees.

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.

See the full analysis of Xintela.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market